|
KMID : 1007420110090010005
|
|
Mood and Emotion
2011 Volume.9 No. 1 p.5 ~ p.11
|
|
|
Efficacy of Atypical Antipsychotics in Depressive Disorder
|
|
Jeong Jong-Hyun
Bahk Won-Myong
|
|
|
Abstract
|
|
|
|
Above 60% of depressive disorder patients may have limited response and remission rates when treated with antidepressants. There are increasing data related to use of atypical antipsychotics as augmentation (strategy of enhancing the antidepressant efficacy) agents in the treatment of non-psychotic, treatment-resistant, unipolar depression. Antidepressant effects of atypical antipsychotics may have been caused by antagonism against 5-HT2A receptor and 5-HT2C receptor, partial agonism of 5-HT1A receptor and dopamine receptor. Aripiprazole and quetiapine have recently been approved from US FDA and KFDA for adjunctive treatment in non-psychotic unipolar depression. Many studies have shown that they reduced depressive symptoms (which could be shown within a week) and increased response and remission rates in lower trial dose than those recommended in schizophrenia or bipolar disorder. Also, olanzapine/fluoxetine combination recently received indication from US FDA for treatment-resistant depression. Paliperidone, metabolite of risperidone, and ziprasidone could be candidates for new adjunctive agents in treatment-resistant depression patients due to their action mechanisms.
|
|
|
KEYWORD
|
|
|
Depression, Atypical antipsychotics, Treatment response
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|